{
    "clinical_study": {
        "@rank": "105757", 
        "arm_group": {
            "arm_group_label": "Mapracorat", 
            "arm_group_type": "Experimental", 
            "description": "Mapracorat ophthalmic suspension, 3%"
        }, 
        "brief_summary": {
            "textblock": "The objective of this study is to evaluate the effect on corneal endothelial cell density\n      (cells/mm\u00b2) changes at 3 months when mapracorat ophthalmic suspension, 3% is administered\n      QID (four times daily), for 14 days in healthy subjects with a normal ophthalmic history."
        }, 
        "brief_title": "Corneal Endothelial Cell Density Changes, When Mapracorat Ophthalmic Suspension 3%, is Administered for 14 Days", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Corneal Endothelial Cell Changes", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Must have a Pinhole visual acuity (VA) equal to or better than 20/40 in both eyes.\n\n          -  Must be in good ocular health\n\n        Exclusion Criteria:\n\n          -  Subjects who have known hypersensitivity or contraindication to the study drug or its\n             components.\n\n          -  Subjects who currently require or are expected to require treatment with any\n             medication listed as a disallowed medication per the Disallowed Therapy section of\n             the protocol.\n\n          -  Any topical ophthalmic medication, including tear substitutes that cannot be\n             discontinued during the study.\n\n          -  Subjects who are monocular (fellow eye is absent or fellow eye's Pinhole VA is worse\n             than 20/200).\n\n          -  Subjects with a history of ocular surgery, or who anticipate ocular surgery in either\n             eye within the study period.\n\n          -  Presence of significant ocular or systemic disease that the Investigator determines\n             could interfere with the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "61", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01736462", 
            "org_study_id": "794"
        }, 
        "intervention": {
            "arm_group_label": "Mapracorat", 
            "description": "One drop of mapracorat ophthalmic suspension, 3% four times daily, at approximately four hour intervals, for 14 days in both eyes.", 
            "intervention_name": "Mapracorat", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Cornea", 
            "Endothelial cell density"
        ], 
        "lastchanged_date": "November 22, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "14609"
                }, 
                "name": "Bausch & Lomb Inc"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label Study to Evaluate 3 Month Corneal Endothelial Cell Density Changes in Healthy Subjects When Mapracorat Ophthalmic Suspension, 3%, is Administered 4 Times Daily for 14 Days", 
        "overall_official": {
            "affiliation": "Bausch & Lomb Incorporated", 
            "last_name": "Quintus Ngumah, OD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The mean endothelial cell density (cells/mm2)(ECD)", 
            "measure": "Endothelial Cell Density", 
            "safety_issue": "No", 
            "time_frame": "3 months (Visit 4)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01736462"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (Ct). Blood samples will be collected for the determination of mapracorat and any potential metabolite(s). Concentrations in plasma measured within 1 hour prior to dosing on day 1 (visit 2).", 
                "measure": "Area under the plasma concentration-time curve", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (Visit 2)"
            }, 
            {
                "description": "Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (Ct). Blood samples will be collected for the determination of mapracorat and any potential metabolite(s). Blood samples will be collected within 1 hour prior to dosing and at 0.25, 0.5, 1, 2, and 4 hours after a single administration of mapracorat at visit 3.", 
                "measure": "Area under the plasma concentration-time curve", 
                "safety_issue": "No", 
                "time_frame": "Day 15 (Visit 3)"
            }
        ], 
        "source": "Bausch & Lomb Incorporated", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bausch & Lomb Incorporated", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}